A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Radafaxine in Patients with Major Depressive Disorder (MDD)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
546
Change in the Montgomery-Asberg Depression Rating Scale (MADRS) score after 8 weeks of treatment
Time frame: 8 Weeks
Change in the MADRS score at other timepoints; change in Clinical Global Impression; percentage of remitters and responders based on the MADRS; change in disability, motivation, energy and pain;incidence of adverse events over course of study.
Time frame: 8 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
GSK Investigational Site
Little Rock, Arkansas, United States
GSK Investigational Site
Newport Beach, California, United States
GSK Investigational Site
Farmington, Connecticut, United States
GSK Investigational Site
Largo, Florida, United States
GSK Investigational Site
Maitland, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
North Miami, Florida, United States
GSK Investigational Site
Edwardsville, Illinois, United States
GSK Investigational Site
Glen Burnie, Maryland, United States
GSK Investigational Site
Farmington Hills, Michigan, United States
...and 19 more locations